NACDS RxImpact Day pushed back due to congressional schedule
ALEXANDRIA, Va. — The National Association of Chain Drug Stores has announced that the dates of the 2012 NACDS RxImpact Day on Capitol Hill in Washington, D.C., have been changed because of an alteration in the 2012 congressional calendar. The new dates for the two-day pharmacy advocacy event will be March 21 and 22, 2012.
The event was previously scheduled for the prior week in March, which now falls during a congressional district work period in which members of Congress will be in their home states and districts.
“There is much at stake with the healthcare delivery system today, and its imperative that pharmacy advocates engage with their elected officials during their visit to Washington, D.C. The rescheduling of the two-day event to March 21 and 22 will now enable pharmacy advocates from across the country to engage with lawmakers on pro-patient and pro-pharmacy issues,” explained NACDS president and CEO Steve Anderson. “In its fourth year, this high-energy event will bring together advocates from all sectors of the industry to meet with key lawmakers to illustrate the unsurpassed value of community pharmacy in improving patient health and reducing costs.”
NACDS will mobilize hundreds pharmacy advocates from all across the country — many wearing pharmacy white coats — during the fourth annual NACDS RxImpact Day on Capitol Hill. The event brings pharmacy and retail executives, division and store managers, pharmacists, pharmacy school deans and students to Washington, D.C., for the two-day event.
Bristol-Myers Squibb, AstraZeneca present analysis of dapagliflozin studies
PRINCETON, N.J. — Bristol-Myers Squibb and AstraZeneca presented an analysis Wednesday of 14 clinical trials at the American Heart Association’s Scientific Sessions in Orlando, Fla., the companies said.
The phase-2b and phase-3 trials all involved the investigational Type 2 diabetes drug dapagliflozin and, the companies said, showed that use of the drug did not lead to an unacceptable risk to adult patients’ cardiovascular health compared with other treatments.
The analysis included 6,228 patients, with 4,287 taking dapagliflozin and 1,941 taking other drugs.
"This comprehensive analysis provides valuable information that can be used to better understand cardiovascular safety profile of dapagliflozin as a monotherapy or as an add-on therapy to common antidiabetic treatments," Bristol-Myers Squibb SVP global development and medical affairs Brian Daniels said.
GSK announces results of late-stage clinical trial for albiglutide
LONDON — GlaxoSmithKline announced the results from the first of eight phase-3 clinical trials that examined the efficacy of albiglutide in the treatment of Type 2 diabetes.
The Harmony 7 trial was a 32-week, head-to-head, open-label, noninferiority study that compared albiglutide, an investigational once weekly glucagon-like peptide-1 agonist, with once-daily liraglutide. According to the results, patients administered GSK’s drug saw a 0.78% reduction in HbA1C, while patients administered liraglutide saw a 0.99% reduction in HbA1C.
“While the prespecified margin of noninferiority was not met, these topline data support continued progression towards registration of albiglutide as a possible future once weekly treatment for Type 2 diabetes,” GSK chairman of research and development Moncef Slaoui said. “This is the first of eight phase-3 studies to conclude and we continue to look forward to receiving the results of the remaining studies which will provide a more complete assessment of the profile of albiglutide in Type 2 diabetes,” he added.
GSK said that initial results from the remaining seven phase-3 studies will become available over the course of the next several months.